Plasma from vaccinated and COVID-19 convalescent subjects as passive immunotherapy against the new Omicron BQ.1.1, XBB, and BF.7 variants biorxivpreprint JohnsHopkinsSPH COVID19 vaccinated covid coronavirus Omicron
By Tarun Sai LomteNov 30 2022Reviewed by Danielle Ellis, B.Sc. In a recent study posted to bioRxiv*, researchers systematically reviewed severe acute respiratory syndrome coronavirus 2 Omicron BQ.1.1 neutralization data from individual patient samples.
The study and findings In the present study, researchers systematically reviewed the literature for data on the neutralization of SARS-CoV-2 Omicron BQ.1.1 by plasma obtained from vaccinated individuals with or without past SARS-CoV-2 infection or those infected recently with Omicron. PubMed, bioRxiv, and medRxiv were searched for research papers reporting BQ.1.1 neutralization.
One study primarily involved individuals with BA.1 or BA.4/5 breakthrough infections and healthcare workers boosted with a monovalent vaccine in the United States . The second study sampled triple-vaccinated subjects in the US before and after receiving a fourth vaccine dose, regardless of their prior infection status.
The last study conducted in the US examined samples after the third vaccination with a monovalent dose and the fourth dose with a monovalent or bivalent vaccine. Subjects across the studies were categorized into three groups – 1) vaccine boosted and had COVID-19 , 2) boosted but self-reported SARS-CoV-2-naïve or were negative for antibodies against nucleocapsid, and 3) Omicron-infected but unvaccinated.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Alterations of the fecal microbiota in relation to acute COVID-19 infection and recovery - Molecular BiomedicinePeople with acute COVID-19 due to SARS-CoV-2 infection experience a range of symptoms, but major factors contributing to severe clinical outcomes remain to be understood. Emerging evidence suggests associations between the gut microbiome and the severity and progression of COVID-19. To better understand the host-microbiota interactions in acute COVID-19, we characterized the intestinal microbiome of patients with active SARS-CoV-2 infection in comparison to recovered patients and uninfected healthy controls. We performed 16S rRNA sequencing of stool samples collected between May 2020 and January 2021 from 20 COVID-19-positive patients, 20 COVID-19-recovered subjects and 20 healthy controls. COVID-19-positive patients had altered microbiome community characteristics compared to the recovered and control subjects, as assessed by both α- and β-diversity differences. In COVID-19-positive patients, we observed depletion of Bacteroidaceae, Ruminococcaceae, and Lachnospiraceae, as well as decreased relative abundances of the genera Faecalibacterium, Adlercreutzia, and the Eubacterium brachy group. The enrichment of Prevotellaceae with COVID-19 infection continued after viral clearance; antibiotic use induced further gut microbiota perturbations in COVID-19-positive patients. In conclusion, we present evidence that acute COVID-19 induces gut microbiota dysbiosis with depletion of particular populations of commensal bacteria, a phenomenon heightened by antibiotic exposure, but the general effects do not persist post-recovery.
Consulte Mais informação »
Study suggests persistent immune activation and long COVID correlate independently with severe COVID-19Researchers investigated whether severe COVID-19 patients exhibited inflammation and immune activation three months after hospitalization and explored the associations among COVID-19 severity, long COVID, and immune activation.
Consulte Mais informação »
Large COVID vaccination study found that thrombosis and thrombocytopenia are very rare complicationsLarge COVID vaccination study found that thrombosis and thrombocytopenia are very rare complications Coronavirus Disease COVID Cardiology Thrombosis Thrombocytopenia NatureComms UniofOxford UV_EG UniBarcelona
Consulte Mais informação »
Isolated monoclonal antibodies targeting SARS-CoV-2 S1/S2 cleavage effective against Delta and OmicronIsolated monoclonal antibodies targeting SARS-CoV-2 S1/S2 cleavage effective against Delta and Omicron Antibodies Coronavirus Disease COVID Delta Omicron SARSCoV2 SciReports UTokyo_News OsakaU_Research gunma_uni_ad
Consulte Mais informação »